Do pharmacogenetics have a role in the dosing of vitamin K antagonists?

New England Journal of Medicine

Volumn 369, Issue 24, 2013, Pages 2345-2346

  Furie, Bruce ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ACENOCOUMAROL; ALBUMIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; PHENPROCOUMON; PROTEIN C; PROTEIN S; PROTHROMBIN; SEMIQUINONE; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ANTICOAGULATION; CYP2C9 GENE; DRUG PROTEIN BINDING; EDITORIAL; ENZYME INHIBITION; GENETIC ALGORITHM; GENETIC VARIABILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTHROMBIN TIME; REACTION ANALYSIS; RESIDUE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THROMBOSIS; VITAMIN K DEFICIENCY; VKORC1 GENE;

EID: 84889871271     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1313682     Document Type: Editorial

References (5)

1. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.
2. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9.
3. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369:2283-93.
4. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369:2304-12.
5. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-303.